Consolidated Statement of Profit or Loss - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2017 |
Dec. 31, 2016 |
Dec. 31, 2015 |
|
| Consolidated Statement of Profit or Loss | |||
| Revenue from settlement and license agreement | $ 1,250,000 | ||
| Cost of the Aditech Pharma AG agreement | (25,000) | ||
| Research and development costs | (20,496) | $ (41,052) | $ (33,727) |
| General and administrative costs | (17,107) | (14,382) | (15,852) |
| Operating income (loss) | 1,187,397 | (55,434) | (49,579) |
| Exchange rate (loss) gain, net | (241) | 598 | 11,933 |
| Interest income | 227 | 389 | 438 |
| Other finance costs | (2,895) | (92) | (132) |
| Income (loss) before tax | 1,184,488 | (54,539) | (37,340) |
| Income tax (expense) benefit | (267,395) | 21,203 | 336 |
| Net income (loss) for the year | 917,093 | (33,336) | (37,004) |
| Net income (loss) for the year attributable to: | |||
| Equity holders of the Parent | $ 917,093 | $ (33,336) | $ (37,004) |
| Per share amounts: | |||
| Net income (loss) per share basic | $ 2.41 | $ (0.06) | $ (0.07) |
| Net income (loss) per share diluted | $ 2.30 | $ (0.06) | $ (0.07) |